Impact Therapeutics KOL Event at ASCO 2022
June 5, 2022
The Impact Therapeutics Team is excited to host a KOL Event at ASCO on Sunday, June 5, 2022, during the 2022 ASCO Annual Meeting.
Dr. Tim Yap from MD Anderson Cancer Center will give a keynote speech on clinical development of DDR agents. Impact’s senior management and PI’s will discuss the company’s pipeline and clinical developments.
For more information, please reach out to Michael at firstname.lastname@example.org
6pm CT - Registration
6:30pm - 9:00pm CT - Event
Impact Therapeutics Inc
The JV is currently conducting a Phase II pivotal study and a Phase III study of Senaparib in ovarian cancer third-line treatment and first-line maintenance treatment in China. Outside China, IMPACT alone is conducting a Phase I/II study of Senaparib and temozolomide combination therapy in solid tumors and small cell lung cancer treatment, as well as a Phase II study of Senaparib monotherapy in prostate cancer maintenance treatment. [more information]